Denise Barrow

4.4k citations

52 papers · 3.6k indexed · h-index 29

Impact in

Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cytokine Signaling Pathways and Interactions
Cancer Research top 5%

Papers in

Oncology 35
- HER2/EGFR in Cancer Research 27
- Cytokine Signaling Pathways and Interactions 8
Genetics 23
- Estrogen and related hormone effects 23

Co-authors: Robert I. Nicholson Julia M.W. Gee Iain R. Hutcheson Janice M. Knowlden Stephen Hiscox Helen E. Jones Alan E. Wakeling M. E. Harper
Journals: Breast Cancer Research and Treatment (7 papers)Breast Cancer Research (6 papers)Endocrine Related Cancer (6 papers)Endocrinology (4 papers)The Prostate (4 papers)
Partner nations: United Kingdom Italy Austria

In The Last Decade

Denise Barrow

50 papers receiving 3.6k citations

Peers

Countries citing papers authored by Denise Barrow

Since Specialization

Citations

This map shows the geographic impact of Denise Barrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise Barrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise Barrow more than expected).

Fields of papers citing papers by Denise Barrow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denise Barrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise Barrow. The network helps show where Denise Barrow may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Denise Barrow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Denise Barrow Line = papers co-authored together Denise Barrow links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors European Journal of Medicinal Chemistry ·C Kaddour, Denise Barrow, Julia M.W. Gee, Talaibaike Maimaijuma, Paul Foster, Claire Simons	2022	8
2	Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance Hormone Molecular Biology and Clinical Investigation ·Julia M.W. Gee, Robert I. Nicholson, Denise Barrow, Carol M. Dutkowski, Lindy Goddard, Nicola Jordan, Richard A. McClelland, Janice M. Knowlden, Hayley E. Francies, Stephen Hiscox, Iain R. Hutcheson	2011	6
3	erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines Breast Cancer Research ·Janice M. Knowlden, Julia M.W. Gee, Denise Barrow, J.F.R. Robertson, Ian O. Ellis, Robert I. Nicholson, Iain R. Hutcheson	2011	20
4	Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance Breast Cancer Research and Treatment ·Janice M. Knowlden, Helen E. Jones, Denise Barrow, Julia M.W. Gee, Robert I. Nicholson, Iain R. Hutcheson	2007	65
5	Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells Breast Cancer Research ·Iain R. Hutcheson, Janice M. Knowlden, Stephen Hiscox, Denise Barrow, Julia M.W. Gee, J.F.R. Robertson, Ian O. Ellis, Robert I. Nicholson	2007	42
6	Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells British Journal of Cancer ·Helen Jones, Julia M.W. Gee, Denise Barrow, R. C. Kirn, B. R. Holloway, R.I. Nicholson	2006	39
7	Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells Breast Cancer Research and Treatment ·Stephen Hiscox, L. Morgan, Tim P. Green, Denise Barrow, Julia M.W. Gee, Robert I. Nicholson	2005	201
8	Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies The Journal of Steroid Biochemistry and Molecular Biology ·R.I. Nicholson, Iain R. Hutcheson, D. Britton, Janice M. Knowlden, Helen Jones, M. E. Harper, Stephen Hiscox, Denise Barrow, Julia M.W. Gee	2005	47
9	Development of strategies for the use of anti-growth factor treatments Endocrine Related Cancer ·Helen E. Jones, Julia M.W. Gee, KM Taylor, Denise Barrow, Корот Лен, Michele Rubini, R.I. Nicholson	2005	31
10	Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract] Breast Cancer Research and Treatment ·Iain R. Hutcheson, Julia M.W. Gee, Denise Barrow, Helen E. Jones, A. E. Wakeling, Robert I. Nicholson	2004	2
11	Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839) Clinical & Experimental Metastasis ·Stephen Hiscox, L. Morgan, Denise Barrow, Carol M. Dutkowski, Alan E. Wakeling, Robert I. Nicholson	2004	93
12	Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells Endocrinology ·Janice M. Knowlden, Iain R. Hutcheson, Helen E. Jones, Tracie‐Ann Madden, Julia M.W. Gee, M. E. Harper, Denise Barrow, Alan E. Wakeling, Robert I. Nicholson	2003	432
13	Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells Breast Cancer Research and Treatment ·Iain R. Hutcheson, Janice M. Knowlden, Tracie‐Ann Madden, Denise Barrow, Julia M.W. Gee, Alan E. Wakeling, Robert I. Nicholson	2003	138
14	Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor The Prostate ·M. E. Harper, Lindy Goddard, James R. Wignall, Jean W. Assender, Carol M. Dutkowski, Denise Barrow, Martina Pytelová, Alan E. Wakeling, Robert I. Nicholson	2002	17
15	Effect of an EGF‐R selective tyrosine kinase inhibitor and an anti‐androgen on LNCaP cells: Identification of divergent growth regulatory pathways The Prostate ·Helen Jones, Denise Barrow, Carol M. Dutkowski, Lindy Goddard, Christopher Smith, M. E. Harper, Tayir Alon	2001	14
16	Non-steroidal and steroidal sulfamates: new drugs for cancer therapy Molecular and Cellular Endocrinology ·A. Purohit, L. W. Lawrence Woo, Denise Barrow, Hatem A Hejaz, R.I. Nicholson, B. V. L. POTTER, Michael Reed	2001	43
17	Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine Related Cancer ·R.I. Nicholson, Iain R. Hutcheson, M. E. Harper, J M Knowlden, Denise Barrow, R A McClelland, Helen E. Jones, A. E. Wakeling, Julia M.W. Gee	2001	131
18	Modulation of oestrogen action by receptor gene inhibition European Journal of Cancer ·F. Bravin, Denise Barrow, R A McClelland, Julia M.W. Gee, Robert I. Nicholson	2000	2
19	Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-α and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines The Prostate ·Helen Jones, Colby L. Eaton, Denise Barrow, Carol M. Dutkowski, Julia M.W. Gee, K. Griffiths	1997	17
20	Response of cell growth and retinoic acid receptor expression to retinoic acid in neoplastic and non-neoplastic prostate cell lines The Prostate ·Helen Jones, Colby L. Eaton, Denise Barrow, Carol M. Dutkowski, K. Griffiths	1997	15

About Denise Barrow

Denise Barrow is a scholar working on Oncology, Genetics, Immunology and Allergy, Endocrinology, Diabetes and Metabolism and Molecular Biology, having authored 52 papers that have together received 3.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (27 papers), Estrogen and related hormone effects (23 papers), PI3K/AKT/mTOR signaling in cancer (10 papers), Growth Hormone and Insulin-like Growth Factors (8 papers), Cytokine Signaling Pathways and Interactions (8 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Metabolism, Diabetes, and Cancer (4 papers) and Lung Cancer Treatments and Mutations (4 papers). The work is most often cited by research in Oncology (1.9k citations), Cancer Research (569 citations), Genetics (1.0k citations), Molecular Biology (1.9k citations) and Toxicology (89 citations). Denise Barrow has collaborated with scholars based in United Kingdom, Italy and Austria. Frequent co-authors include Robert I. Nicholson, Julia M.W. Gee, Iain R. Hutcheson, Janice M. Knowlden, Stephen Hiscox, Helen E. Jones, Alan E. Wakeling, M. E. Harper, Tracie‐Ann Madden and L. Morgan. Their work appears in journals such as Breast Cancer Research and Treatment, Breast Cancer Research, Endocrine Related Cancer, Endocrinology and The Prostate.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact